Chronic inhibition of 11 β -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Schnackenberg, Christine G ^a   Costell, Melissa H ^a   Krosky, Daniel J ^a   Cui, Jianqi ^a   Wu, Charlene W ^a   Hong, Victor S ^a   Harpel, Mark R ^a   Willette, Robert N ^a   Yue, Tian Li ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CHLORIDE; CHOLESTEROL; CREATININE; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; RENIN; SODIUM; TRIACYLGLYCEROL; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; GLUCOCORTICOID; LEPTIN RECEPTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSURIA; HEART RATE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; KIDNEY FUNCTION; LEAN BODY WEIGHT; LIVER; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; MICROALBUMINURIA; MICTURITION; NONHUMAN; OBESITY; PLASMA RENIN ACTIVITY; POTASSIUM EXCRETION; RAT; SODIUM EXCRETION; STEROID METABOLISM; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; WEIGHT GAIN; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER; METABOLIC SYNDROME X; OBESITY; RATS; RECEPTORS, LEPTIN; WEIGHT GAIN;

EID: 84876545898     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/427640     Document Type: Article

References (54)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). The Journal of the American Medical Association 2001 285 19 2486 2497 2-s2.0-0035897696
2. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C., Spertus J. A., Costa F., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005 112 17 2735 2752 2-s2.0-27444443876 10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
3. Lorenzo C., Williams K., Hunt K. J., Haffner S. M., Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio heart study. Diabetes Care 2006 29 3 625 630 2-s2.0-33744985985 (Pubitemid 44115364)
4. Ford E. S., Giles W. H., Mokdad A. H., Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004 27 10 2444 2449 2-s2.0-4644279733 10.2337/diacare.27.10.2444 (Pubitemid 39281399)
5. Walker B. R., Glucocorticoids and cardiovascular disease. European Journal of Endocrinology 2007 157 5 545 559 2-s2.0-36549001222 10.1530/EJE-07-0455 (Pubitemid 350187371)
6. Goodwin J. E., Geller D. S., Glucocorticoid-induced hypertension. Pedatric Nephrology 2012 27 7 1059 1066
7. Chrousos G. P., Kino T., Intracellular glucocorticoid signaling: a formerly simple system turns stochastic. Science's STKE 2005 2005 304 pe48 2-s2.0-33644875471
8. Hermanowski-Vosatka A., Balkovec J. M., Cheng K., Chen H. Y., Hernandez M., Koo G. C., Le Grand C. B., Li Z., Metzger J. M., Mundt S. S., Noonan H., Nunes C. N., Olson S. H., Pikounis B., Ren N., Robertson N., Schaeffer J. M., Shah K., Springer M. S., Strack A. M., Strowski M., Wu K., Wu T., Xiao J., Zhang B. B., Wright S. D., Thieringer R., 11 β -HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. The Journal of Experimental Medicine 2005 202 4 517 527 2-s2.0-23944493717 10.1084/jem.20050119 (Pubitemid 41186950)
9. Small G. R., Hadoke P. W. F., Sharif I., Dover A. R., Armour D., Kenyon C. J., Gray G. A., Walker B. R., Preventing local regeneration of qlucocorticoids by 11 β -hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2005 102 34 12165 12170 2-s2.0-24744448423 10.1073/pnas.0500641102 (Pubitemid 41291146)
10. Hautanen A., Räikkönen K., Adlercreutz H., Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. Journal of Internal Medicine 1997 241 6 451 461 2-s2.0-0030746916 (Pubitemid 27315825)
11. Walker B. R., Phillips D. I. W., Noon J. P., Panarelli M., Andrew R., Edwards H. V., Holton D. W., Seckl J. R., Webb D. J., Watt G. C. M., Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998 31 4 891 895 2-s2.0-0031899323 (Pubitemid 28185563)
12. Filipovský J., Ducimetière P., Eschwège E., Richard J. L., Rosselin G., Claude J. R., The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. Journal of Hypertension 1996 14 2 229 235 2-s2.0-0029879029 10.1097/00004872-199602000-00012 (Pubitemid 26121866)
13. Walker B. R., Campbell J. C., Fraser R., Stewart P. M., Edwards C. R. W., Mineralocorticoid excess and inhibition of 11 β -hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clinical Endocrinology 1992 37 6 483 492 2-s2.0-0026441301
14. Magiakou M. A., Smyrnaki P., Chrousos G. P., Hypertension in Cushing's syndrome. Best Practice and Research 2006 20 3 467 482 2-s2.0-33748641219 10.1016/j.beem.2006.07.006 (Pubitemid 44382381)
15. Monder C., White P. C., 11 β -hydroxysteroid dehydrogenase. Vitamins and Hormones 1993 47 187 271 2-s2.0-0027346746 10.1016/S0083-6729(08)60447-1
16. Walker B. R., Campbell J. C., Williams B. C., Edwards C. R. W., Tissue-specific distribution of the NAD+-dependent isoform of 11 β-hydroxysteroid dehydrogenase. Endocrinology 1992 131 2 970 972 2-s2.0-0026671792 10.1210/en.131.2.970
17. Smith R. E., Maguire J. A., Stein-Oakley A. N., Sasano H., Takahashi K. I., Fukushima K., Krozowski Z. S., Localization of 11 β -hydroxysteroid dehydrogenase type II in human epithelial tissues. Journal of Clinical Endocrinology and Metabolism 1996 81 9 3244 3248 2-s2.0-0029847770 10.1210/jc.81.9.3244 (Pubitemid 26296195)
18. Ulick S., Levine L. S., Gunczler P., A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. Journal of Clinical Endocrinology and Metabolism 1979 49 5 757 764 2-s2.0-0018598286 (Pubitemid 10198311)
19. Stewart P. M., Corrie J. E. T., Shackleton C. H. L., Edwards C. R. W., Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. Journal of Clinical Investigation 1988 82 1 340 349 2-s2.0-0023760499 (Pubitemid 18262536)
20. Paterson J. M., Morton N. M., Fievet C., Kenyon C. J., Holmes M. C., Staels B., Seckl J. R., Mullins J. J., Metabolic syndrome without obesity: hepatic overexpression of 11 β -hydroxysteroid dehydrogenase type 1 in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2004 101 18 7088 7093 2-s2.0-2342510149 10.1073/pnas. 0305524101 (Pubitemid 38596447)
21. Masuzaki H., Yamamoto H., Kenyon C. J., Elmquist J. K., Morton N. M., Paterson J. M., Shinyama H., Sharp M. G. F., Fleming S., Mullins J. J., Seckl J. R., Flier J. S., Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. Journal of Clinical Investigation 2003 112 1 83 90 2-s2.0-0041302382 10.1172/JCI200317845 (Pubitemid 38056379)
22. Kotelevtsev Y., Holmes M. C., Burchell A., Houston P. M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C. R. W., Seckl J. R., Mullins J. J., 11 β -Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proceedings of the National Academy of Sciences of the United States of America 1997 94 26 14924 14929 2-s2.0-0031283178 10.1073/pnas.94.26.14924 (Pubitemid 28041476)
23. Feig P. U., Shah S., Hermanowski-Vosatka A., Plotkin D., Springer M. S., Donahue S., Thach C., Klein E. J., Lai E., Kaufman K. D., Effects of an 11 β -hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes, Obesity and Metabolism 2011 13 6 498 504 2-s2.0-79955046317 10.1111/j.1463-1326.2011.01375.x
24. Shah S., Hermanowski-Vosatka A., Gibson K., Ruck R. A., Jia G., Zhang J., Hwang P. M. T., Ryan N. W., Langdon R. B., Feig P. U., Efficacy and safety of the selective 11 β -HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. Journal of the American Society of Hypertension 2011 5 3 166 176 2-s2.0-79955639922 10.1016/j.jash.2011.01.009
25. Nagase M., Matsui H., Shibata S., Gotoda T., Fujita T., Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007 50 5 877 883 2-s2.0-35848952953 10.1161/HYPERTENSIONAHA.107.091058 (Pubitemid 350287529)
26. Kagota S., Yamaguchi Y., Tanaka N., Kubota Y., Kobayashi K., Nejime N., Nakamura K., Kunitomo M., Shinozuka K., Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sciences 2006 78 11 1187 1196 2-s2.0-31744433920 10.1016/j.lfs.2005.06.029 (Pubitemid 43176713)
27. Michaelis O. E., Ellwood K. C., Judge J. M., Effect of dietary sucrose on the SHR/N-corpulent rat: a new model for insulin-independent diabetes. American Journal of Clinical Nutrition 1984 39 4 612 618 2-s2.0-0021278994 (Pubitemid 14135375)
28. Gu X., Dragovic J., Koo G. C., Koprak S. L., Legrand C., Mundt S. S., Shah K., Springer M. S., Tan E. Y., Thieringer R., Hermanowski-Vosatka A., Zokian H. J., Balkovec J. M., Waddell S. T., Discovery of 4-heteroarylbicyclo[2. 2.2]octyltriazoles as potent and selective inhibitors of 11 β -HSD1: novel therapeutic agents for the treatment of metabolic syndrome. Bioorganic and Medicinal Chemistry Letters 2005 15 23 5266 5269 2-s2.0-26844460594 10.1016/j.bmcl.2005.08.052 (Pubitemid 41463661)
29. Livingstone D. E. W., Kenyon C. J., Walker B. R., Mechanisms of dysregulation of 11 β -hydroxysteroid dehydrogenase type I in obese zucker rats. The Journal of Endocrinology 2000 167 3 533 539 2-s2.0-0034519393 10.1677/joe.0.1670533 (Pubitemid 32047561)
30. Lu A. Y. H., Levin W., Partial purification of cytochromes P-450 and P-448 from rat liver microsomes. Biochemical and Biophysical Research Communications 1972 46 3 1334 1339 2-s2.0-0015512089
31. Mundt S., Solly K., Thieringer R., Hermanowski-Vosatka A., Development and application of a scintillation proximity assay (SPA) for identification of selectiive inhibitors of 11 β -hydroxysteroid dehydrogenase type 1. Assay and Drug Development Technologies 2005 3 4 367 375 2-s2.0-27144431970 10.1089/adt.2005.3.367 (Pubitemid 41489392)
32. Solly K., Mundt S. S., Zokian H. J., Ding G. J. F., Hermanowski-Vosatka A., Strulovici B., Zheng W., High-throughput screening of 11 β -hydroxysteroid dehydrogenase type 1 scintillation proximity assay format. Assay and Drug Development Technologies 2005 3 4 377 384 2-s2.0-27144542109 10.1089/adt.2005.3.377 (Pubitemid 41489393)
33. Walker B. R., Best R., Shackleton C. H. L., Padfield P. L., Edwards C. R. W., Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996 27 2 190 196 2-s2.0-0030023440 (Pubitemid 26045916)
34. Soro A., Ingram M. C., Tonolo G., Glorioso N., Fraser R., Evidence of coexisting changes in 11 β -hydroxysteroid dehydrogenase and 5 β -reductase activity in subjects with untreated essential hypertension. Hypertension 1995 25 1 67 70 2-s2.0-0028967443
35. Walker B. R., Stewart P. M., Shackleton C. H. L., Padfield P. L., Edwards C. R. W., Deficient inactivation of cortisol by 11 β -hydroxysteroid dehydrogenase in essential hypertension. Clinical Endocrinology 1993 39 2 221 227 2-s2.0-0027320739 (Pubitemid 23224295)
36. Campino C., Carvajal C. A., Cornejo J., Martín B. S., Olivieri O., Guidi G., Faccini G., Pasini F., Sateler J., Baudrand R., Mosso L., Owen G. I., Kalergis A. M., Padilla O., Fardella C. E., 11 β -hydroxysteroid dehydrogenase type-2 and type-1 (11 β -HSD2 and 11 β -HSD1) and 5 β -reductase activities in the pathogenia of essential hypertension. Endocrine 2010 37 1 106 114 2-s2.0-75949084447 10.1007/s12020-009-9269-9
37. Walker B. R., Phillips D. I. W., Noon J. P., Panarelli M., Andrew R., Edwards H. V., Holton D. W., Seckl J. R., Webb D. J., Watt G. C. M., Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998 31 4 891 895 2-s2.0-0031899323 (Pubitemid 28185563)
38. Kidambi S., Kotchen J. M., Grim C. E., Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007 49 3 704 711 2-s2.0-33847063910
39. Schnackenberg C. G., 11 β -hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome. Current Opinion in Investigational Drugs 2008 9 3 295 300 2-s2.0-40049094652 (Pubitemid 351323383)
40. Hu X., Bolten C. W., Adrenal corticosteroids, their receptors and hypertension. Drug Development Research 2006 67 12 871 883 2-s2.0-34247260606 10.1002/ddr.20158 (Pubitemid 46606736)
41. Hadoke P. W. F., Macdonald L., Logie J. J., Small G. R., Dover A. R., Walker B. R., Intra-vascular glucocorticoid metabolism as a modulator of vascular structure and function. Cellular and Molecular Life Sciences 2006 63 5 565 578 2-s2.0-33645081473 10.1007/s00018-005-5427-2
42. Wang S. J. Y., Birtles S., de Schoolmeester J., Swales J., Moody G., Hislop D., O'Dowd J., Smith D. M., Turnbull A. V., Arch J. R. S., Inhibition of 11 β -hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006 49 6 1333 1337 2-s2.0-33646516612 10.1007/s00125-006-0239-y
43. Hall J. E., Brands M. W., Zappe D. H., Galicia M. A., Insulin resistance, hyperinsulinemia, and hypertension: causes, consequences, or merely correlations? Proceedings of the Society for Experimental Biology and Medicine 1995 208 4 317 329 2-s2.0-0028949464
44. Klett C., Ganten D., Hellmann W., Kaling M., Ryffel G. U., Weimar-Ehl T., Hackenthal E., Regulation of hepatic angiotensinogen synthesis and secretion by steroid hormones. Endocrinology 1992 130 6 3660 3668 2-s2.0-0026718030 10.1210/en.130.6.3660
45. Sato A., Suzuki H., Murakami M., Nakazato Y., Iwaita Y., Saruta T., Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994 23 1 25 30 2-s2.0-0028120892 (Pubitemid 24022040)
46. Nangaku M., Miyata T., Sada T., Mizuno M., Inagi R., Ueda Y., Ishikawa N., Yuzawa H., Koike H., Van Ypersele De Strihou C., Kurokawa K., Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. Journal of the American Society of Nephrology 2003 14 5 1212 1222 2-s2.0-0037407792 10.1097/01.ASN.0000062961.76776.C1 (Pubitemid 36514663)
47. Nagase M., Yoshida S., Shibata S., Nagase T., Gotoda T., Ando K., Fujita T., Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. Journal of the American Society of Nephrology 2006 17 12 3438 3446 2-s2.0-33845238078 10.1681/ASN.2006080944 (Pubitemid 44865286)
48. Gross M. L., Ritz E., Schoof A., Helmke B., Parkman A., Tulp O., Münter K., Amann K., Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Laboratory Investigation 2003 83 9 1267 1277 2-s2.0-0141590203 10.1097/01.LAB.0000085188.23709.29 (Pubitemid 37140311)
49. Yamaguchi Y., Yamada K., Yoshikawa N., Nakamura K., Haginaka J., Kunitomo M., Corosolic acid prevents oxidative stress, inflammation and hypertension in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sciences 2006 79 26 2474 2479 2-s2.0-33750972570 10.1016/j.lfs.2006.08.007 (Pubitemid 44750017)
50. Hussein G., Nakagawa T., Goto H., Shimada Y., Matsumoto K., Sankawa U., Watanabe H., Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sciences 2007 80 6 522 529 2-s2.0-33845939627 10.1016/j.lfs.2006.09.041 (Pubitemid 46038324)
51. Obunai K., Jani S., Dangas G. D., Cardiovascular morbidity and mortality of the metabolic syndrome. Medical Clinics of North America 2007 91 6 1169 1184 2-s2.0-35548964739 10.1016/j.mcna.2007.06.003 (Pubitemid 350010914)
52. Ferrannini E., Buzzigoli G., Bonadonna R., Insulin resistance in essential hypertension. The New England Journal of Medicine 1987 317 6 350 357 2-s2.0-0023191508 (Pubitemid 17118813)
53. Swislocki A. L. M., Hoffman B. B., Reaven G. M., Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. American Journal of Hypertension 1989 2 6 419 423 2-s2.0-0024348392 (Pubitemid 19168223)
54. Zavaroni I., Mazza S., Dall'Aglio E., Gasparini P., Passeri M., Reaven G. M., Prevalence of hyperinsulinaemia in patients with high blood pressure. Journal of Internal Medicine 1992 231 3 235 240 2-s2.0-0026586950